dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-07. Numbers and descriptions here follow the published literature rather than marketing material.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
== Principle == Salt compounds dissociate in aqueous solutions. This property is exploited in the process of salting out. When the salt concentration is increased, some of the water molecules are attracted by the salt ions, which decreases the number of water molecules available to interact with the charged part of the protein.
=== Procedures === More advanced cases may be resistant or unresponsive to medical therapy and require hair transplantation. Naturally occurring units of one to four hairs, called follicular units, are excised and moved to areas of hair restoration. These follicular units are surgically implanted in the scalp in proximity and in large numbers. The grafts are obtained from either follicular unit transplantation (FUT) or follicular unit extraction (FUE). In the former, a strip of skin with follicular units is extracted and dissected into individual follicular unit grafts, and in the latter, individual hairs are extracted manually or robotically. The surgeon then implants the grafts into small incisions, called recipient sites. Cosmetic scalp tattoos can also mimic the appearance of a short, buzzed haircut.
=== EC 1.14.1 With NADH or NADPH as one donor (deleted sub-subclass) === EC 1.14.1.1: now EC 1.14.14.1, unspecific monooxygenase EC 1.14.1.2: now EC 1.14.13.9, kynurenine 3-monooxygenase EC 1.14.1.3: deleted, covered by EC 1.14.99.7, squalene monooxygenase and EC 5.4.99.7, lanosterol synthase EC 1.14.1.4: now EC 1.14.99.2, kynurenine 7,8-hydroxylase EC 1.14.1.5: now EC 1.14.13.5; imidazoleacetate 4-monooxygenase EC 1.14.1.6: now EC 1.14.15.4, steroid 11β-monooxygenase EC 1.14.1.7: now EC 1.14.99.9, steroid 17α-monooxygenase EC 1.14.1.8: now EC 1.14.99.10, steroid 21-monooxygenase EC 1.14.1.9: deleted EC 1.14.1.10: now EC 1.14.99.11 estradiol 6β-monooxygenase EC 1.14.1.11: deleted
Sources: en.wikipedia.org
Peter Giles later called it one of Fripp's "cute political moves". According to Michael Giles, his brother had become disillusioned with the band's lack of success and departed before Fripp ever made this suggestion.
== Sports == A 2017 INSEE study reported persistent gender disparities in physical and sports activities. Women were underrepresented in racket and team sports. In media coverage, women's sports accounted for less than 20% of televised sports airtime. Leadership roles in sports organizations remain limited for women. Despite the 2014 law for real gender equality, in 2019 only one Olympic sports federation and eleven non-Olympic federations were led by women.
A metatarsophalangeal joint sprain is an injury to the connective tissue between the foot and a toe (at a metatarsophalangeal joint, one of the joints in the ball of the foot). When the big toe is involved, it is known as "turf toe".
=== Scalar nature === In a static gas, the gas as a whole does not appear to move. The individual molecules of the gas, however, are in constant random motion. Because there are an extremely large number of molecules and because the motion of the individual molecules is random in every direction, no motion is detected. When the gas is at least partially confined (that is, not free to expand rapidly), the gas will exhibit a hydrostatic pressure. This confinement can be achieved with either a physical container, or in the gravitational well of a large mass, such as a planet, otherwise known as atmospheric pressure. In the case of planetary atmospheres, the pressure-gradient force of the gas pushing outwards from higher pressure, lower altitudes to lower pressure, higher altitudes is balanced by the gravitational force, preventing the gas from diffusing into outer space and maintaining hydrostatic equilibrium. In a physical container, the pressure of the gas originates from the molecules colliding with the walls of the container. The walls of the container can be anywhere inside the gas, and the force per unit area (the pressure) is the same. If the "container" is shrunk down to a very small point (becoming less true as the atomic scale is approached), the pressure will still have a single value at that point. Therefore, pressure is a scalar quantity, not a vector quantity. It has magnitude but no direction sense associated with it. Pressure force acts in all directions at a point inside a gas.
Sources: en.wikipedia.org
μ is the dynamic viscosity of the fluid (Pa·s = N·s/m2 = kg/(m·s)); Q is the volumetric flow rate, used here to measure flow instead of mean velocity according to Q = π/4Dc2<v> (m3/s). Note that this laminar form of Darcy–Weisbach is equivalent to the Hagen–Poiseuille equation, which is analytically derived from the Navier–Stokes equations.
=== Health care === Albany is served by Samaritan Albany General Hospital, a 76-bed medical facility that is the main hospital for the city and has been in operation since 1924. Albany is also served by Samaritan North Albany Urgent Care and Geary Street Urgent Care, both of which are part of Samaritan Health Services. The unaffiliated Albany Family & Specialty Medicine also provides medical services to the community.
Insulin-degrading enzyme (IDE) (also known as insulinase, insulin protease, or insulysin) is a large zinc-binding protease of the M16 metalloprotease family of enzymes. It is known to cleave multiple short polypeptides that vary considerably in sequence, including insulin. Other members of this family include the mitochondrial processing peptidase and presequence protease. Insulin-degrading enzyme is coded for in the human by the IDE gene.
=== Nanomaterials === Nanoparticles are used for several antimicrobial applications due to their extraordinary behavior. More studies are being carried out on the ability of nanomaterials to be utilized for antimicrobial coatings due to their highly reactive nature.
There were also communist states in Africa, such as Ethiopia. In 1974, the military overthrew Emperor Haile Selassie and installed a military junta known as the Derg. The Derg quickly aligned itself with the Soviet Union on the basis of communism, implementing Marxist-Leninist ideals that were radical for their country. The brutal imposition of their radical ideas led to a debilitating civil war. In 1977, after a series of political purges and executions, Mengistu Haile Mariam became the leader of the Derg. He continued this course and brought Ethiopia closer to the USSR, which became Ethiopia's main trading partner, supplying it with everything from weapons and equipment to military advisers and specialists. Mengistu ultimately built a highly militarized state with the largest army in sub-Saharan Africa. The Soviet Union pushed Mengistu to create a "People's Democratic" system, as was the case in the Eastern Bloc countries, but Mengistu did so very reluctantly: Ethiopia became the "People's Democratic Republic of Ethiopia" only in 1987. And although the Derg was formally dissolved, roughly the same people remained in power as before. In the other four existing socialist and people's democratic states, namely China, Cuba, Laos, and Vietnam, the ruling parties hold Marxism–Leninism as their official ideology, although they give it different interpretations in terms of practical policy. Marxism–Leninism is also the ideology of anti-revisionist, Hoxhaist, Maoist, and neo-Stalinist communist parties worldwide.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.